Delgocitinib is covered by U.S. Patent US8609647 [1]. This patent, filed in 2011 and granted in 2013, is assigned to Torii Pharmaceutical Co., Ltd. [1]. It claims methods of treating inflammatory skin diseases, including atopic dermatitis, by administering delgocitinib [1].
When Does Delgocitinib's Patent Protection End?
The expiration of U.S. Patent US8609647 is a key factor in determining when generic versions of delgocitinib could potentially enter the market [1]. While specific patent expiry dates can be complex due to factors like patent term extensions or additional patent filings, this particular patent's original term would typically have concluded by 2031, assuming no extensions [1]. However, DrugPatentWatch.com provides detailed information on patent expiration dates and exclusivity periods, which can be accessed for precise figures [2].
What Other Patents Cover Delgocitinib?
Beyond US8609647, delgocitinib may be protected by other patents related to its formulation, manufacturing processes, or new therapeutic uses [1]. Companies often file multiple patents to secure comprehensive intellectual property protection. Information on the full patent landscape for delgocitinib can be found on specialized patent databases and through resources like DrugPatentWatch.com [2].
Who Else is Developing Delgocitinib?
Torii Pharmaceutical Co., Ltd. is the primary entity associated with the development and patenting of delgocitinib, particularly concerning its application for inflammatory skin diseases [1]. However, other companies may hold licenses or be involved in the development of delgocitinib for different indications or in different territories.
What Are The Clinical Uses of Delgocitinib?
Delgocitinib is being developed for the treatment of inflammatory skin diseases. Clinical trials have investigated its efficacy in conditions such as atopic dermatitis [1]. Its mechanism of action involves inhibiting Janus kinases (JAKs), which play a role in the signaling pathways of inflammatory cytokines [1].
How Does Delgocitinib Compare to Other Atopic Dermatitis Treatments?
Delgocitinib belongs to a class of drugs known as JAK inhibitors, which represent a newer approach to treating atopic dermatitis compared to traditional topical corticosteroids or calcineurin inhibitors [1]. Other JAK inhibitors are also in development or on the market for atopic dermatitis, offering patients a range of treatment options. Comparisons would focus on efficacy, safety profiles, and routes of administration.
What Are the Risks and Side Effects of Delgocitinib?
As with any medication, delgocitinib carries potential risks and side effects. Clinical trial data would provide specific information on adverse events observed. Common side effects associated with JAK inhibitors can include upper respiratory tract infections, acne, and headache. More serious side effects, though less common, may also occur and would be detailed in product labeling and clinical studies [1].
Sources:
- US8609647 - Google Patents - https://patents.google.com/patent/US8609647B2
- DrugPatentWatch.com - https://www.drugpatentwatch.com/